300436 广生堂
已收盘 12-12 15:00:00
资讯
新帖
简况
广生堂：GST-HG141 III期临床暂无中期揭盲计划
证券之星 · 12-03
广生堂：GST-HG141 III期临床暂无中期揭盲计划
广生堂：创新药GST-HG141临床三期试验正按计划推进
证券之星 · 11-20
广生堂：创新药GST-HG141临床三期试验正按计划推进
股市必读：广生堂三季报 - 第三季度单季净利润同比下降29.75%
中金财经 · 10-31
股市必读：广生堂三季报 - 第三季度单季净利润同比下降29.75%
图解广生堂三季报：第三季度单季净利润同比下降29.75%
证券之星 · 10-30
图解广生堂三季报：第三季度单季净利润同比下降29.75%
广生堂(300436.SZ)发布前三季度业绩，归母净亏损1.12亿元
智通财经 · 10-30
广生堂(300436.SZ)发布前三季度业绩，归母净亏损1.12亿元
广生堂：乙肝治疗创新药III期临床试验进展顺利
证券之星 · 10-29
广生堂：乙肝治疗创新药III期临床试验进展顺利
股市必读：广生堂（300436）10月28日董秘有最新回复
证券之星 · 10-29
股市必读：广生堂（300436）10月28日董秘有最新回复
广生堂：公司目前未开展流感疫苗的研发、生产和销售
证券之星 · 10-28
广生堂：公司目前未开展流感疫苗的研发、生产和销售
广生堂：公司注册地位于宁德柘荣
证券之星 · 10-28
广生堂：公司注册地位于宁德柘荣
股市必读：广生堂（300436）10月24日董秘有最新回复
证券之星 · 10-27
股市必读：广生堂（300436）10月24日董秘有最新回复
广生堂（300436）披露控股子公司股权转让及增资扩股完成工商变更，10月23日股价下跌1.67%
证券之星 · 10-23
广生堂（300436）披露控股子公司股权转让及增资扩股完成工商变更，10月23日股价下跌1.67%
股价高位回撤35%，“中药茅”Q3净利继续“崩盘”
《投资有道》杂志 · 10-22
股价高位回撤35%，“中药茅”Q3净利继续“崩盘”
广生堂：创新药子公司获近2亿元增资
证券之星 · 10-17
广生堂：创新药子公司获近2亿元增资
突发异动！300436，涨停！
中国基金报 · 10-15
突发异动！300436，涨停！
异动快报：广生堂（300436）10月15日10点19分触及涨停板
证券之星 · 10-15
异动快报：广生堂（300436）10月15日10点19分触及涨停板
广生堂最新公告：乙肝治疗一类创新药GST-HG131研究成果被美国肝病研究协会接受为年会最新突破摘要报告
证券之星 · 10-10
广生堂最新公告：乙肝治疗一类创新药GST-HG131研究成果被美国肝病研究协会接受为年会最新突破摘要报告
广生堂：GST-HG141已完成III期临床首例患者入组
证券之星 · 09-26
广生堂：GST-HG141已完成III期临床首例患者入组
广生堂：乙肝治疗创新药GST-HG141完成III期临床试验首例患者入组
证券之星 · 09-16
广生堂：乙肝治疗创新药GST-HG141完成III期临床试验首例患者入组
股市必读：广生堂（300436）新发布《关于公司申请向特定对象发行股票的审核问询函回复（修订稿）及募集说明书等申请文件更新的提示性公告》
证券之星 · 09-09
股市必读：广生堂（300436）新发布《关于公司申请向特定对象发行股票的审核问询函回复（修订稿）及募集说明书等申请文件更新的提示性公告》
广生堂：本次增资扩股事宜仍在推进中
证券之星 · 09-05
广生堂：本次增资扩股事宜仍在推进中
加载更多
公司概况
公司名称：
福建广生堂药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-04-22
主营业务：
福建广生堂药业股份有限公司的主营业务是核苷类抗乙肝病毒药物的研发、生产与销售。公司的主要产品是丙酚替诺福韦、替诺福韦、恩替卡韦、拉米夫定、阿德福韦酯五大核苷（酸）类抗乙肝病毒用药。公司获第二十三届中国国际高新技术成果交易会“优秀产品奖”。
发行价格：
21.47
{"stockData":{"symbol":"300436","market":"SZ","secType":"STK","nameCN":"广生堂","latestPrice":90.48,"timestamp":1765522980000,"preClose":89.57,"halted":0,"volume":4294800,"delay":0,"changeRate":0.0102,"floatShares":137000000,"shares":159000000,"eps":-1.2385,"marketStatus":"已收盘","change":0.91,"latestTime":"12-12 15:00:00","open":88.88,"high":90.92,"low":87.7,"amount":385000000,"amplitude":0.0359,"askPrice":90.49,"askSize":10,"bidPrice":90.48,"bidSize":133,"shortable":0,"etf":0,"ttmEps":-1.2385,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":89.57,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":98.53,"lowLimit":80.61,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":159267000,"isCdr":false,"pbRate":37.24,"roa":"--","roe":"--","epsLYR":-0.9814,"committee":0.365462,"marketValue":14410000000,"turnoverRate":0.0314,"status":0,"floatMarketCap":12370000000},"requestUrl":"/m/hq/s/300436","defaultTab":"news","newsList":[{"id":"2588750046","title":"广生堂：GST-HG141 III期临床暂无中期揭盲计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2588750046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588750046?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:51","pubTimestamp":1764766288,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂(300436)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好: 请问广生堂141三期临床会不会出中期数据？如果会的话大概在什么时候出？广生堂回复：尊敬的投资者，您好！GST-HG141的III期临床试验是一项48周治疗的随机双盲研究，是公司创新药研发管线的重点项目，正按计划全力推进。为确保数据的完整性，公司目前暂未安排该试验中期揭盲分析计划。公司将持续高效推进试验进程并及时披露创新药重大进展，感谢您的关注和支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2584131758","title":"广生堂：创新药GST-HG141临床三期试验正按计划推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2584131758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584131758?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:51","pubTimestamp":1763643090,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂11月19日在投资者关系平台上答复投资者关心的问题。公司是否应该适时公布入组人数进展，让广大投资者安心广生堂回复：投资者，您好。今年7月首例患者入组的是公司乙肝治疗创新药GST-HG141的临床三期试验，目前正按计划顺利推进。截至目前具体的患者入组人数涉及临床试验的保密性，且为避免对临床进展不必要的干扰，暂不便对外披露，请您理解。公司将在创新药研究重大进展时及时履行信息披露，感谢您的关注！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000035562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","300436","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2579710017","title":"股市必读：广生堂三季报 - 第三季度单季净利润同比下降29.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579710017","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579710017?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:17","pubTimestamp":1761869852,"startTime":"0","endTime":"0","summary":"股东户数变动截至2025年9月30日，广生堂股东户数为4.58万户，较6月30日增加2.55万户，增幅125.95%；户均持股数量由7858.0股降至3478.0股，户均持股市值为34.4万元。财务报告广生堂2025年三季报显示，前三季度主营收入3.16亿元，同比下降3.21%；归母净利润-1.12亿元，同比下降57.96%；扣非净利润-1.18亿元，同比下降40.81%。2025年第三季度单季度主营收入1.07亿元，同比下降1.07%；单季度归母净利润-4489.63万元，同比下降29.75%；单季度扣非净利润-4709.95万元，同比下降32.46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251031/31754312.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300436"],"gpt_icon":0},{"id":"2579180639","title":"图解广生堂三季报：第三季度单季净利润同比下降29.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579180639","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579180639?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:22","pubTimestamp":1761765733,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂2025年三季报显示，前三季度公司主营收入3.16亿元，同比下降3.21%；归母净利润-1.12亿元，同比下降57.96%；扣非净利润-1.18亿元，同比下降40.81%；其中2025年第三季度，公司单季度主营收入1.07亿元，同比下降1.07%；单季度归母净利润-4489.63万元，同比下降29.75%；单季度扣非净利润-4709.95万元，同比下降32.46%；负债率69.18%，投资收益-243.17万元，财务费用2469.45万元，毛利率61.91%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436"],"gpt_icon":0},{"id":"2579189189","title":"广生堂(300436.SZ)发布前三季度业绩，归母净亏损1.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579189189","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579189189?lang=zh_cn&edition=full","pubTime":"2025-10-30 01:13","pubTimestamp":1761758033,"startTime":"0","endTime":"0","summary":"智通财经APP讯，广生堂(300436.SZ)发布2025年三季度报告，该公司前三季度营业收入为3.16亿元，同比减少3.21%。归属于上市公司股东的净亏损为1.12亿元。归属于上市公司股东的扣除非经常性损益的净亏损为1.18亿元。基本每股亏损为0.7006元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"广生堂(300436.SZ)发布前三季度业绩，归母净亏损1.12亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2579061329","title":"广生堂：乙肝治疗创新药III期临床试验进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2579061329","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579061329?lang=zh_cn&edition=full","pubTime":"2025-10-29 20:51","pubTimestamp":1761742305,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂(300436)10月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司在创新药研发领域有没有新的突破？广生堂回复：投资者，您好！创新药的研发是一场需要耐心与毅力的长征。目前，公司创新药研发各项工作正按计划稳步推进，乙肝治疗创新药GST-HG141的III期临床试验在全国多家临床中心持续入组，进展顺利。公司将全力推进创新药研发，后续如有阶段性重大进展，公司将依照信息披露相关规定及时披露，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900042187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","BK1161","159992","BK1574","300436"],"gpt_icon":0},{"id":"2579960813","title":"股市必读：广生堂（300436）10月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579960813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579960813?lang=zh_cn&edition=full","pubTime":"2025-10-29 01:32","pubTimestamp":1761672737,"startTime":"0","endTime":"0","summary":"截至2025年10月28日收盘，广生堂报收于114.47元，下跌2.33%，换手率6.71%，成交量9.17万手，成交额10.57亿元。董秘最新回复投资者： 董秘您好：据新闻报道中国疾控中心日前发布的流感监测周报显示，目前我国南方省份流感活动上升。公司目前未开展流感疫苗的研发、生产和销售。目前公司未涉及两岸合作相关业务。当日关注点来自交易信息汇总：10月28日主力资金净流出6120.41万元，显示主力资金大幅离场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900002264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2578335649","title":"广生堂：公司目前未开展流感疫苗的研发、生产和销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2578335649","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578335649?lang=zh_cn&edition=full","pubTime":"2025-10-28 16:45","pubTimestamp":1761641116,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂(300436)10月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好：据新闻报道中国疾控中心日前发布的流感监测周报显示，目前我国南方省份流感活动上升。专家预测，受多方面因素影响，今年我国的流感流行季可能提前到来，流行毒株也与去年不同感染人数会更多，请问公司是否有研发和销售针对流感疫苗类产品？请先关介绍一下。感谢回复广生堂回复：尊敬的投资者，您好！公司目前未开展流感疫苗的研发、生产和销售。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800029198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2578593933","title":"广生堂：公司注册地位于宁德柘荣","url":"https://stock-news.laohu8.com/highlight/detail?id=2578593933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578593933?lang=zh_cn&edition=full","pubTime":"2025-10-28 16:39","pubTimestamp":1761640755,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂10月28日在投资者关系平台上答复投资者关心的问题。请相关介绍一下广生堂回复：尊敬的投资者，您好！目前公司未涉及两岸合作相关业务。公司注册地位于宁德柘荣，同时将总部设在福州，欢迎来“有福之州”考察指导！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800029050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2578656165","title":"股市必读：广生堂（300436）10月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2578656165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578656165?lang=zh_cn&edition=full","pubTime":"2025-10-27 00:45","pubTimestamp":1761497113,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，广生堂报收于114.96元，下跌0.37%，换手率6.95%，成交量9.5万手，成交额10.92亿元。董秘最新回复投资者： 董事长您好；请问公司现在有董秘吗？别的公司都是积极耐心的回复投资者的提问，建议公司加急处理此事。公司高度重视互动易平台与投资者的沟通交流，如确实存在部分回复不及时的情况，我们深表歉意，后续会持续改进。当日关注点来自交易信息汇总：10月24日主力资金净流出6758.43万元，散户资金净流入6850.44万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2577112371","title":"广生堂（300436）披露控股子公司股权转让及增资扩股完成工商变更，10月23日股价下跌1.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577112371","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577112371?lang=zh_cn&edition=full","pubTime":"2025-10-23 17:04","pubTimestamp":1761210270,"startTime":"0","endTime":"0","summary":"截至2025年10月23日收盘，广生堂报收于115.39元，较前一交易日下跌1.67%，最新总市值为183.78亿元。公司近日发布公告称，控股子公司福建广生中霖生物科技有限公司已完成股权转让及增资扩股的工商变更登记，并取得新的营业执照。根据公告，广生中霖注册资本由38,850万元增至41,823.60万元，广生堂对其持股比例由81.0811%变更为75.3163%，广生中霖仍为公司控股子公司，不导致合并报表范围变更。公司表示，已收到全部增资款19,135.1351万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300025688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2577535031","title":"股价高位回撤35%，“中药茅”Q3净利继续“崩盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=2577535031","media":"《投资有道》杂志","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577535031?lang=zh_cn&edition=full","pubTime":"2025-10-22 17:37","pubTimestamp":1761125820,"startTime":"0","endTime":"0","summary":"“中药茅”片仔癀三季报正式出炉，净利润连续两个季度大幅下滑。片仔癀则处于“双下滑”队列，营收同比下滑4.81%，归母净利润同比下滑16.22%。2025年上半年，片仔癀的销售毛利率为40.41%，在行业中排名第52位。股价回撤35%，近一年大宗交易成交超2.8亿元三季报发出后，片仔癀股价连续三天下跌。片仔癀的市值一度接近3000亿元，被市场称为“中药茅”。而在2025年上半年，片仔癀归母净利润较上年同期减少约2.8亿元，扣非归母净利润减少约2.98亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-22/doc-infuuiip0388695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0572939691.SGD","BK0175","BK0187","LU1328615791.USD","BK0015","300436","BK0276","BK0239","600739","601166","LU1580142542.USD","BK0196","LU1048596156.SGD","600062","LU1781817850.SGD","BK0188","600436","BK0144","BK0250","BK0010","601377","BK0012","LU0821914370.USD","BK0183","BK0028","LU0572940350.SGD","BK0074","BK0185","LU0264606111.USD","BK0278"],"gpt_icon":0},{"id":"2576082656","title":"广生堂：创新药子公司获近2亿元增资","url":"https://stock-news.laohu8.com/highlight/detail?id=2576082656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576082656?lang=zh_cn&edition=full","pubTime":"2025-10-17 16:30","pubTimestamp":1760689834,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂10月17日在投资者关系平台上答复投资者关心的问题。希望李董事长认真考虑，谢谢.广生堂回复：感谢您对公司创新药业务的关注与宝贵建议。今年9月，公司已公告创新药子公司广生中霖已成功引入重要投资者实施股权增资近2亿元，为创新研发提供了保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700025486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","300436","BK1574","159992","BK0239","06978"],"gpt_icon":0},{"id":"2575220486","title":"突发异动！300436，涨停！","url":"https://stock-news.laohu8.com/highlight/detail?id=2575220486","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575220486?lang=zh_cn&edition=full","pubTime":"2025-10-15 12:58","pubTimestamp":1760504280,"startTime":"0","endTime":"0","summary":"创新药板块异动拉升，大消费板块表现活跃中国基金报记者 李智10月15日，A股三大指数冲高回落，截至午间收盘，沪指涨0.10%，创业板指涨0.22%。创新药概念股异动拉升创新药概念股异动拉升，广生堂20%涨停，舒泰神涨超10%，博腾股份、华海药业、美迪西等涨幅靠前。此外，制药板块多数走强，济民健康、昂利康、联环药业等多股涨停。消息面上，近日，经济形势专家和企业家座谈会召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656315384&idx=2&sn=98a43442c05d669f30c910f13becc99e&chksm=8a66fd8ca7d3267fc763f8cc246bd1d776c18b16c2a04b262cc36a4869a0863ba437522d2a1a&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656315384&idx=2&sn=98a43442c05d669f30c910f13becc99e&chksm=8a66fd8ca7d3267fc763f8cc246bd1d776c18b16c2a04b262cc36a4869a0863ba437522d2a1a&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2575327826","title":"异动快报：广生堂（300436）10月15日10点19分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2575327826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575327826?lang=zh_cn&edition=full","pubTime":"2025-10-15 10:20","pubTimestamp":1760494830,"startTime":"0","endTime":"0","summary":"证券之星10月15日盘中消息，10点19分广生堂触及涨停板。目前价格122.65，上涨20.0%。其所属行业化学制药目前上涨。该股为肝炎概念，创新药，医药概念热股，当日肝炎概念概念上涨2.65%，创新药概念上涨2.22%，医药概念上涨1.83%。10月14日的资金流向数据方面，主力资金净流出2693.97万元，占总成交额2.12%，游资资金净流入532.97万元，占总成交额0.42%，散户资金净流入2161.0万元，占总成交额1.7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500011073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2574173810","title":"广生堂最新公告：乙肝治疗一类创新药GST-HG131研究成果被美国肝病研究协会接受为年会最新突破摘要报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2574173810","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574173810?lang=zh_cn&edition=full","pubTime":"2025-10-10 19:29","pubTimestamp":1760095796,"startTime":"0","endTime":"0","summary":"广生堂公告称，公司创新药控股子公司福建广生中霖生物科技有限公司收到美国肝病研究协会的通知，乙肝治疗一类创新药GST-HG131的临床II期研究结果被正式接受为最新突破摘要口头报告。GST-HG131是全球首个完成II期临床的口服HBsAg抑制剂，具有良好可及性和患者依从性。其II期临床试验显示，HBsAg下降迅速，最高降幅达97.71%。此外，GST-HG131联合GST-HG141针对乙肝经治患者的II期临床试验项目有望挑战乙肝临床治愈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000033774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","06978","300436","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2570288655","title":"广生堂：GST-HG141已完成III期临床首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2570288655","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570288655?lang=zh_cn&edition=full","pubTime":"2025-09-26 20:52","pubTimestamp":1758891163,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂09月26日在投资者关系平台上答复投资者关心的问题。公司乙肝治疗创新药GST-HG141已于2025年7月完成III期临床试验的首例患者入组，进度处于行业同品类前列。GST-HG131联合GST-HG141用于慢性乙型肝炎治疗的II期临床试验项目已获批临床。目前GST-HG141的III期临床正在全国多个中心稳步推进。创新药研发是公司发展的核心驱动力，公司必将全力以赴，同时对研发进展按照相关规定履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600036469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0},{"id":"2567100912","title":"广生堂：乙肝治疗创新药GST-HG141完成III期临床试验首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2567100912","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567100912?lang=zh_cn&edition=full","pubTime":"2025-09-16 20:52","pubTimestamp":1758027143,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂09月16日在投资者关系平台上答复投资者关心的问题。公司乙肝治疗创新药GST-HG141已于2025年7月完成III期临床试验的首例患者入组，进度处于行业同品类前列。公司基于多年在乙肝治疗领域的深耕，形成了具有自身特色的乙肝创新药多管线布局和联合治疗策略，且拥有从研发、生产到商业化销售的一体化能力，为产品未来上市及患者可及性提供坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600035869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","06978","300436","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2566063570","title":"股市必读：广生堂（300436）新发布《关于公司申请向特定对象发行股票的审核问询函回复（修订稿）及募集说明书等申请文件更新的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2566063570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566063570?lang=zh_cn&edition=full","pubTime":"2025-09-09 01:15","pubTimestamp":1757351716,"startTime":"0","endTime":"0","summary":"截至2025年9月8日收盘，广生堂报收于113.38元，上涨0.01%，换手率8.06%，成交量11.02万手，成交额12.46亿元。公司公告汇总福建广生堂药业股份有限公司拟向特定对象发行A股股票，募集资金总额不超过97,686.65万元，用于创新药研发项目、中药传统名方产业化项目及补充流动资金。本次发行股票数量不超过47,780,100股，发行对象不超过35名，限售期6个月。截至2025年6月30日，公司不存在重大违法违规行为。本次发行尚需经深交所审核通过并获得中国证监会注册。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090900001155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300436"],"gpt_icon":0},{"id":"2565535904","title":"广生堂：本次增资扩股事宜仍在推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2565535904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565535904?lang=zh_cn&edition=full","pubTime":"2025-09-05 11:37","pubTimestamp":1757043430,"startTime":"0","endTime":"0","summary":"证券之星消息，广生堂09月05日在投资者关系平台上答复投资者关心的问题。一旦广生中霖创新药陆续上市后，必将产生大量的利润，而本次广生中霖股权被稀释，也会使控股母公司每股利润被稀释。目前增资扩股事宜仍在推进中，交易的实施仍存在不确定性，敬请注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500015499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300436","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765617645334,"stockEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.1325},{"period":"3month","weight":-0.246},{"period":"6month","weight":1.6565},{"period":"1year","weight":1.6135},{"period":"ytd","weight":1.7695}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"福建广生堂药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"45797人(较上一季度增加125.95%)","perCapita":"2985股","listingDate":"2015-04-22","address":"福建省宁德市柘荣县富源工业园区1-7幢","registeredCapital":"15926万元","survey":" 福建广生堂药业股份有限公司的主营业务是核苷类抗乙肝病毒药物的研发、生产与销售。公司的主要产品是丙酚替诺福韦、替诺福韦、恩替卡韦、拉米夫定、阿德福韦酯五大核苷（酸）类抗乙肝病毒用药。公司获第二十三届中国国际高新技术成果交易会“优秀产品奖”。","listedPrice":21.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"广生堂(300436)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供广生堂(300436)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"广生堂,300436,广生堂股票,广生堂股票老虎,广生堂股票老虎国际,广生堂行情,广生堂股票行情,广生堂股价,广生堂股市,广生堂股票价格,广生堂股票交易,广生堂股票购买,广生堂股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"广生堂(300436)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供广生堂(300436)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}